0000000000454669

AUTHOR

Oliver D. Howes

showing 3 related works from this author

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidep…

2021

Contains fulltext : 238693.pdf (Publisher’s version ) (Open Access) Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic …

Drugmedicine.medical_specialtyprecision medicinetherapeutic drug monitoringmedia_common.quotation_subjectStress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13]brain imagingNeuroimagingPsykiatri03 medical and health sciences0302 clinical medicinePharmacotherapyNeuroimagingmedicineHumansIntensive care medicineBiological Psychiatrypharmacogeneticsmedia_commonPsychiatrymedicine.diagnostic_testbusiness.industryAntidepressantsPrecision medicineAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTherapeutic drug monitoringPharmacogeneticsAntidepressants; brain imaging; pharmacogenetics; precision medicine; therapeutic drug monitoring; Antidepressive Agents; Drug Monitoring; Humans; Neuroimaging; Pharmacogenetics; PsychiatryAntidepressants; brain imaging; precision medicine; pharmacogenetics; therapeutic drug monitoringDrug MonitoringbusinessPharmacogeneticsWorld Journal of Biological Psychiatry
researchProduct

30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed into the Developmental Risk Factor Model of Psychosis

2017

At its re-birth 30 years ago, the neurodevelopment hypothesis of schizophrenia focussed on aberrant genes and early neural hazards, but then it grew to include ideas concerning aberrant synaptic pruning in adolescence. The hypothesis had its own stormy development and it endured some difficult teenage years when a resurgence of interest in neurodegeneration threatened its survival. In early adult life, it over-reached itself with some reductionists claiming that schizophrenia was simply a neurodevelopmental disease. However, by age 30, the hypothesis has matured sufficiently to incorporated childhood and adult adversity, urban living and migration, as well as heavy cannabis use, as importan…

Striatal dopaminePsychosismedicine.medical_specialtyDopamineSynaptic pruningDiseaseHistory 21st CenturyRisk factor model03 medical and health sciences0302 clinical medicinesociodevelopmentmedicineHumansrisk factorsPsychiatryUrban livingPsychiatryneurodevelopmentdopamine neurodevelopment risk factors sociodevelopment Dopamine History 20th Century History 21st Century Humans Psychiatry Psychotic Disorders SchizophreniaHistory 20th Centurymedicine.disease030227 psychiatryPsychiatry and Mental healthAdult lifemedicine.anatomical_structurePsychotic DisordersSchizophreniaSchizophreniadopaminePsychology030217 neurology & neurosurgeryRegular ArticlesClinical psychology
researchProduct

Vitamin D and clinical symptoms in First Episode Psychosis (FEP): A prospective cohort study

2019

BACKGROUND: There is a paucity of longitudinal research investigating vitamin D in people with early psychosis.METHOD: Vitamin D levels were measured in 168 patients (64% (n = 108) male, mean age 29.3 (9.8) years) with first episode psychosis (FEP), along with measures of clinical state at baseline and at 12 months follow up. We assessed the a) cross sectional, and; b) longitudinal relationships between continuous and categorical 25-hydroxyvitamin D (25(OH)D) levels and clinical symptoms at first contact for psychosis and at 12 months.RESULTS: In FEP, 80% (n = 134) at baseline, and 76% at 12 months follow up, had suboptimal vitamin D levels (<20 ng/ml). Suboptimal levels of 25 (OH) D at …

AdultMalemedicine.medical_specialtyPsychosisCognitiveCross-sectional studyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineFirst episode psychosismedicineVitamin D and neurologyHumansLongitudinal StudiesProspective Studies25-hydroxyvitamin D (25(OH)D)Vitamin DYoung adultProspective cohort studyBiological PsychiatryNegative symptombusiness.industryFEPPsychosismedicine.disease030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesPsychotic DisordersSchizophreniaLongitudinalSchizophreniaFemaleNegative symptomsbusiness030217 neurology & neurosurgerySchizophrenia Research
researchProduct